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The human skin fulﬁlls important barrier, sensory, and immune functions—all of which contribute signiﬁcantly to health and
organism integrity. Widespread skin damage requires immediate treatment and coverage because massive skin loss fosters the
invasion of pathogens, causes critical ﬂuid loss, and may ultimately lead to death. Since the skin is a highly immunocompetent
organ, autologous transplants are the only viable approach to permanently close a widespread skin wound. Despite the
development of tissue-saving autologous transplantation techniques such as mesh and Meek grafts, treatment options for
extensive skin damage remain severely limited. Yet, the skin is also a rich source of stem and progenitor cells. These cells
promote wound healing under physiological conditions and are potential sources for tissue engineering approaches aiming to
augment transplantable tissue by generating cultured epidermal autografts (CEAs). Here, we review autologous tissue
engineering strategies as well as transplantation products based on skin-derived stem cells. We further provide an overview of
clinical trial activities in the ﬁeld and discuss relevant translational and clinical challenges associated with the use of these products.
1. Introduction
The skin is among the largest human organs. In addition to
its important sensory function, it forms an eﬀective barrier
that is pivotal for organism integrity. The skin shields the
organism from detrimental environmental inﬂuences or
infections and maintains a proper ﬂuid balance. It is also
one of the most immune-active organs and hosts cellular ele-
ments of the innate and adaptive immune system that imme-
diately attack pathogens, should they manage to cross the
physical and chemical barrier provided by the epidermis.
Massive and widespread skin damage exceeds the regen-
erative capacity of the skin, which represents a signiﬁcant
threat to the entire organism and requires timely and eﬀec-
tive therapeutic intervention. Moreover, widespread skin
lesions often result from burns with thermal damage
additionally impairing skin regeneration. Finally, the regen-
erative capacity of the skin also declines with age, which
may necessitate interventions to support wound healing in
the elderly.
On the other hand, the skin exhibits a tremendous regen-
erative potential. Unique stem and progenitor cells reside in
the skin and its appendages (e.g., hair bulbs and sweat
glands) [1–4] and are suﬃcient to counter light and moderate
skin injury under physiological conditions. These cell popu-
lations have been of interest for regenerative medicine
approaches since the 1970s to overcome the limitations of
conventional skin grafting techniques. A number of thera-
peutic strategies have already been developed with the poten-
tial to thoroughly promote wound healing or replace
irreversibly lost skin areas. Consequently, these treatment
strategies have been advanced into the clinical arena. In this
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review, we summarize advances in using skin-derived stem
cells and products thereof and monitor the past and recent
clinical trial activities in the ﬁeld. We also identify potential
challenges in translation and clinical use that need to be
addressed by future research to increase the beneﬁt for
patients suﬀering from complicated skin wounds.
2. Conventional Grafting Techniques
and Allografts
2.1. Autologous Skin Transplantation. Autologous skin graft-
ing techniques can be used to cover large skin defects [5, 6].
For this, skin is taken from another body area of the same
patient and widened by cutting and stretching procedures
before wound covering (mesh orMeek graft transplantation).
Although indispensable for the treatment of severe and large
skin wounds, conventional autograft procedures come with
some critical limitations. First, autologous skin grafting
induces secondary wounds to the patient’s skin, which them-
selves are signiﬁcant when dealing with larger lesions. Sec-
ond, massive skin injury resulting from burns, aggressive
acidic and alkaline chemicals, or physical stress can cause
lesions that are too large to be eﬀectively treated. Third, local
blood supply can be impaired, preventing physiological skin
regeneration or engraftment. The latter is the case in chronic
or diabetic ulcers in the elderly.
2.2. Allografts. To overcome some of the problems associated
with autologous skin transplantation, skin from other human
beings (allografts) or even diﬀerent species (xenografts) is
used. The risk of transmitting a communicable disease can-
not be entirely excluded in these approaches [7], but is min-
imal under modern good manufacturing practice (GMP)
conditions and in allografts built from well-characterized
cell lines. Premanufactured allografts are cryopreserved
and therefore available as oﬀ-the-shelf products. Allograft
cryopreservation prior to application results in similar clin-
ical outcome in comparison to fresh graft transplantation
onto skin ulcers [8]. However, there is no long-term
engraftment of major histocompatibility complex (MHC)
and blood type-mismatched allografts [9]. Allografts are
usually rejected after a mean of 14.5 days, showing signs
of acute cutaneous graft versus host disease in histological
investigations, but exceptions have also been reported [10].
Rather than engraftment, allografts likely work due to phys-
ical wound closure as well as stimulation of endogenous
skin regeneration.
Another approach to reduce the immunological response
is the use of cell-free biomaterials. One example is Allo-
derm®, an allogeneic product from a decellularized dermis
consisting of collagen ﬁbers and glycosaminoglycans covered
by a silicon layer [11]. The product is preferentially applied to
deeper wounds. This artiﬁcial dermis does not only prevent
ﬂuid loss and evaporation from the wound, but also induces
cellular proliferation and angiogenesis. These processes sus-
tainably support natural dermis regeneration [12]. Other
examples in widespread clinical use are cell-free, xenogenic
products such as Matriderm® and Integra® [13, 14].
Such biomaterials are also available in combination with
living cells, which support wound healing. Stratagraft® is a
product derived from an immortalized human keratinocyte
cell line, NIKS (normal immortal keratinocytes), forming a
top layer over a dermal ﬁbroblast matrix. Another example
is Apligraf®, a collagen matrix containing keratinocytes and
ﬁbroblasts of human neonatal foreskin, which shows high
proliferative capacity and may have a slightly better immu-
nologic proﬁle. While Stratagraft is primarily employed to
treat burn wounds, Apligraf is used to treat leg and diabetic
foot ulcers. Epidermal allografts transplanted onto chronic
ulcers improve reepithelialization from wound edges and
skin appendages, augment granulation tissue, and foster
rebuilding of the basement membrane [8, 10, 15].
3. Skin-Derived Stem Cells
To overcome immunological problems and the scarce skin
availability, cells isolated from small skin biopsies can be
propagated in vitro and cultivated on biomaterials to cover
skin wounds. These materials are called cultured epidermal
autografts (CEAs). CEAs are for instance derived from
unpuriﬁed epidermal cell cultures that are thought to contain
epidermal stem cells.
3.1. Epidermal Stem Cells. The ﬁrst in vitro cultivation of
human epidermal keratinocytes forming epidermis-like tis-
sue was reported in 1975 [16]. A mixed cell population
containing epidermal stem cells (epi-SCs) was applied in
the 1980s and 1990s to treat grade II and III burn victims.
Multiple CEAs with a cumulative surface area of up to
1.9m2 (Table 1) were obtained from few small healthy skin
biopsies [17]. Although cosmetic results obtained in these
early studies were still not optimal, wound healing was signif-
icantly improved. Compared to conventionally treated
patients, wound surface reduction was accelerated with
regenerated skin being more durable and stable [18–20].
Table 1: Comparison between epi-SC- and hf-SC-derived CEAs.
Aspect epi-SCs hf-SCs References
Reported donor age 0 to 59 years 63 to 91 years [22, 65, 80]
Cultivation period 3 to 4 weeks 4 weeks [25, 66, 81]
Material required Skin biopsy (3 cm2) 40 to 350 anagen hair follicles [28, 66, 82]
CEA surface
0.8 cm2 single-CEA surface or larger up to 1.9m2
in total can be generated for one patient
0.8 cm2 single-CEA surface [17, 22, 23]
Engraftment rate 70%, high variability 80 to 90% [18, 19, 82]
2 Stem Cells International
CEAs are used in a number of clinical scenarios, but alter-
native application methods also exist. One approach is to
prepare a suspension of autologous epi-SC-derived keratino-
cytes. This suspension is sprayed onto large burn or chronic
wounds showing impaired healing [21]. The procedure is
suﬃcient as a stand-alone treatment of small- and moder-
ately sized, superﬁcial wounds. It signiﬁcantly improves
wound healing and reduces scar formation. The approach
is, however, not ideally suited for the treatment of large
and/or deeper wounds that usually require additional mesh
or Meek grafts. A logistically and cosmetically relevant
advantage of the spraying approach is that the wound
induced by the skin biopsy can itself be treated with the spray.
3.2. Hair Follicle-Derived Epithelial Stem Cells. Hair follicle-
derived epithelial stem cells (hf-SCs) are obtained from ana-
gen hair follicles. CEAs generated from these cells are used to
treat chronic wounds (predominantly venous ulcers) and
have already been applied for more than 20 years [22, 23].
A commercially available autologous product based on hf-
SCs called EpiDex® is in clinical use since 2004. About 4
weeks are required to cultivate numerous small EpiDex discs
of about 1 cm in diameter (Table 1). Interestingly, donor
(patient) age has no inﬂuence on cell proliferation [24] and
the overall eﬃcacy of the approach. EpiDex is typically
applied to small and moderately sized chronic wounds exhi-
biting granulation but not reepithelialization. A long-term
study performed between 2004 and 2008 revealed that Epi-
Dex treatment induced complete wound healing in 3 out of
4 cases within a 9-month surveillance period [24].
4. Clinical Use of CEAs
The ﬁrst transplantations of human CEAs in a clinical case
series were conducted in 1980 [25]. Two patients suﬀering
from partial and full-thickness burns on 80% and 40% of
their body surface area, respectively, were treated with split-
thickness skin grafts and epi-SC-derived CEAs. Direct com-
parison between the two transplantation methods did not
indicate diﬀerences in graft contraction or fragility. Although
there were diﬀerences compared to what is found in normal
skin, regenerating skin spreading in from the wound edges
resulted in similar tissue histology [25].
The durability of CEAs was further demonstrated by two
cases, in which children suﬀering burns continued to live
for at least 20 years after being transplanted with cultured
autologous equivalents in the early 1980s [26, 27]. Moreover,
a female burn victim experienced normal pregnancy despite
the previous abdominal transplantation of CEAs grown on
a ﬁbrin matrix [28]. This demonstrates that CEAs do not
only provide tissue replacement and homeostasis, but can
also grow and adapt to mechanical stress, a decisive feature
for improving quality of life after transplantation, particu-
larly in young patients.
Based on the early successes in burn victims, a wide spec-
trum of possible applications other than burns was assessed
over the years. For instance, skin defects following pyoderma
gangrenosum [29], excision of congenital nevi [30], separa-
tion of conjoined twins resulting in large wounds on the left
side of the thoracic and abdominal walls [31] as well as
in vitiligo [32] and chronic leg ulcers [33] were treated
with CEAs. Furthermore, an autologous method for junc-
tional epidermolysis bullosa (JEB) treatment was reported
in 2006. A retroviral vector expressing LAMB3 cDNA was
used to manufacture genetically modiﬁed CEAs for a JEB
patient. Transplantation of these grafts resulted in adherent
and completely functional epidermis. No complications were
reported during the 1-year follow-up period [34]. Lenti- and
retroviral vectors as well as a ϕC31 integrase-based gene
correction method were also investigated for (recessive)
dystrophic epidermolysis bullosa [35–38]. Transfected epi-
SC-derived CEAs exhibited regular distribution of type VII
collagen as well as normal epidermal diﬀerentiation andmor-
phology for at least 12 months in a xenogeneic (human-
mouse) transplantation model [38]. A clinical study using
this retroviral vector is currently ongoing (NCT01263379).
In a very recent single-case clinical intervention, a pediatric
patient suﬀering from severe and life-threatening JEB was
treated with genetically corrected epidermal sheets derived
from a 4 cm2 autologous skin biopsy [39]. Outcome was
highly encouraging and the treatment concept has the poten-
tial to be widely applied.
Currently, there are only few commercial CEAs available
on the market. Among these are Epicel® (Vericel, USA),
ReCell® (Avita Medical, UK), and MySkin® (Regenerys,
UK), the latter being an unlicensed medicinal product. Epicel
is prepared as a sheet and MySkin as a single-cell suspension.
Both are produced under GMP conditions. ReCell is not a
cell product, but a device for preparing a cell suspension from
a single-skin biopsy directly in the clinic. The suspension is
sprayed on to the lesioned area.
4.1. Beneﬁts of CEAs. The main advantage of CEAs compared
to conventional skin autografts for the treatment of compli-
cated or chronic wounds is that it does not require a second
skin wound, which itself can be prone to complications such
as pain, infection, retarded healing, and scar formation [40].
For this purpose, the scalp is an advantageous skin source as
it contains abundant hair follicles (leading to better epitheli-
alization) and any potential scars can be covered relatively
easily. The biopsy process is well tolerated and avoids larger
secondary wounds [38]. Epi-SCs are usually obtained via skin
biopsy under local anesthesia, whereas hf-SCs are acquired
by hair follicle plucking without the need for anesthesia.
After grafting, patients need to be immobilized only
shortly, if at all [23]. One reason for this is that CEAs lead
to slightly thinner but more elastic epidermis formation.
Moreover, application of CEAs reduces wound contraction
as compared to conventional approaches, and hypertrophic
scar formation is less frequent [41]. Wounds display only
minimal contraction, but maintain excellent tissue ﬂexibility
when treated with epi-SCs cultivated in ﬁbrinogen-derived
ﬁbrin glue, made of ﬁbrinogen, ﬁbronectin, and factor XIII.
Hence, this approach is particularly feasible for areas under
intensive and/or complex mechanical stress [28] such as the
eyelid, ﬁngers, or toes. Furthermore, epi-SCs cultivated in
the ﬁbrinogen matrix provided by the glue form a stable cell
layer, which is easy to handle during transplantation and
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shows excellent adhesion to thewound surface [42]. The com-
bination with allografts is also possible, as the top silicon layer
of Alloderm can be removed and replaced by a CEA [43].
4.2. Overview of Clinical Trial Activities. To achieve an
overview on recent activities in the application of CEAs,
we performed a literature and database search on “http://
pubmed.gov/” and “http://clinicaltrials.gov/”. Search terms
are provided in Supplementary Table 1. Our search revealed
155 clinical trials and single-case reports being performed
and published between 1981 and 2016. Skin-derived stem
cells and related products were used in both clinical trials
and single-case treatments (Figure 1). Early clinical activi-
ties reported in the 1980s and 1990s were primarily single-
case reports. Phase I (safety) studies started to emerge around
1990. Studies including secondary or primary eﬃcacy end-
points (phases II to IV) were conducted since 2005, indicat-
ing the step-wise development and progression of tested
approaches and products.
Of note, new phase I clinical trials have not been
launched since 2013, and a considerable proportion of clini-
cal studies were not completed as planned. In particular, only
12 out of 40 studies (30%) listed on “http://clinicaltrials.gov/”
have been completed as originally intended. Another 13
(32.5%) studies are still active, with 11 studies (27.5%) cur-
rently recruiting patients. A total number of 15 studies
(37.5%) were terminated, withdrawn, or have an unknown
status. This means that at least about one-third of all studies
were not performed as planned. Moreover, some of the
completed studies ended without recruiting the prespeciﬁed
patient numbers; hence, it is unclear whether the remain-
ing 11 studies currently enrolling patients can be completed
as planned.
The shortage of studies in the last years may indicate the
potential challenges hampering clinical implementation of
stemcell-based skin regeneration approaches. In the following
paragraphs, we will highlight unmet research needs reﬂecting
such challenges in skin wound treatment using CEAs.
5. Unmet Research Needs and Challenges
5.1. Preclinical Research. Results from in vivo models can
usually not be completely transferred to the clinical situation
in experimental dermatology and wound healing. This is par-
tially due to interspecies diﬀerences. Compared to murine
skin, which represents the most popular in vivo model in
experimental dermatology, for instance, humans have thicker
epidermal and dermal layers containing more cells. Further-
more, human skin contains fewer but larger hair follicles
while the interfollicular epidermis is wider-spaced [44, 45].
Human skin also exhibits rete ridges and a number of basic
immune system diﬀerences [44–46]. For example, surface
proteins of human and mouse hf-SCs are not congruent [47].
Skin contraction is an important feature in rodent wound
healing, but is not observed in humans and thus may lead to
an overestimation of treatment eﬀects as compared to human
patients [48]. A number of measures have been developed to
counter these eﬀects in rodent models, including the use of
chambers or polypropylene rings and tetanized meshes that
are transplanted into the skin defect to impair wound
contraction [49–51]. Suturing the wound edges to underlying
tissue is also performed to stabilize the defect [52]. Although
these techniques are eﬀective in preventing skin contraction
in rodents, they interfere with the wound healing process
and therefore cannot fully compensate for interspecies biases
in preclinical in vivo wound healing studies. One option is to
use large animal models for conﬁrmative studies in the ﬁeld.
Pig skin is more similar to human skin and porcine models
may provide valuable advantages in translational research
[53]. However, the overall number of large animal studies
on wound healing, even when including neighboring areas
of skin regeneration research, is limited to only a few key
publications [54–56]. This may partially be due to the overall
higher costs and eﬀorts of large animal research [57]. Never-
theless, the use of more advanced in vivo or, alternatively,
ex vivo wound healing models more adequately representing
human skin pathophysiology is encouraged.
5.2. CEA Production and Treatment Costs. One of the major
disadvantages of CEA is its relatively long production time of
3 to 4 weeks (Table 1), which is problematic when treating
large-sized and complicated skin wounds. To solve this prob-
lem, a two-step wound treatment approach can be applied.
Initially, an allograft is transplanted for wound coverage as
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Figure 1: Number and type of clinical trials for stem cell-based skin
regeneration since 1980. Single-case studies or small series of single
cases were the main clinical activities reported before 1989.
Subsequently, the number of phase I trials (safety) increased,
reaching its ﬁrst peak in the mid-1990s, followed by phase II
studies (safety and secondary eﬃcacy endpoints) since the early
2000s. Large, late-stage clinical phase III (eﬃcacy) and phase IV
(surveillance of products on market) studies were reported since
2005, which was accompanied by a drop in single-case reports.
Remarkably, no additional phase I clinical trial has been launched
since 2013. Only studies reported in http://pubmed.com and/or
listed on http://clinicaltrials.gov were included in this analysis. The
search was restricted to studies reported between 1981 and 2016.
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the generation of patient-speciﬁc CEA autografts, which are
subsequently transplanted.
The relatively high costs associated with the use of CEAs
present another challenge preventing widespread applica-
tion. In the late 1990s, treating 1% of the surface area of the
body after burns was estimated to cost US$600 for CEAs
cultured on ﬁbrin and US$1350 for autografts cultured on
special plastics [58], and costs may have further increased
since then. The cost per square centimeter with deﬁnitive
engraftment and wound closure in children was calculated
to be around US$6520. A comparable treatment in adults is
even more expensive (US$13,000), with a reported deﬁnitive
engraftment rate of just 4.6%, questioning the cost-
eﬀectiveness of such treatments in adults [59]. Daily care
expenses for a burn victim treated with an epidermal auto-
graft amount to US$4500, clearly exceeding the costs of a
conventional treatment (US$3500) [59]. High treatment
costs, in part being caused by the indispensable, but labor-
intensive and expensive manual GMP production, are there-
fore a relevant aspect at least partially explaining why stem
cell-derived CEAs are not yet routinely and widely applied.
Manual GMP production gives a relatively small product
output [28]. The overall high production costs can only be
covered if there is a high and continuous request for CEAs,
but the demand often remains behind expectations. This
may explain frequently observed bankruptcy in skin regener-
ation companies [60]. Step-wise implementation of automa-
tion technology into the production chain may help to lower
overall production costs. An alternative would be the utiliza-
tion of simpliﬁed, on-site cell isolation procedures from
autologous skin or subdermal fat tissue, but it needs to be
shown that the therapeutic outcome in the clinics compares
to the promising preclinical data [61] and results obtained
by CEAs currently in use.
On the other hand, a cost-eﬀectiveness study in children
with massive burns, conducted in the late 1990s, revealed that
burn sites treated with cultured grafts show less extensive
scar formation compared to those treated with mesh grafts
[62]. This may warrant the treatment particularly in younger
patients, even though treatment with CEAs is associated with
longer hospital stays. In addition, patients treated with CEAs
had to undergo more reconstructive procedures during the
ﬁrst two years after treatment [62]. Although good clinical
experience was made [63], a recent and detailed cost calcula-
tion for EpiDex in the treatment of leg ulcers still reported
signiﬁcant treatment costs. However, the direct comparison
of EpiDex and split-thickness skin grafting for a single
average treatment resulted in a better cost-eﬀectiveness in
favor of EpiDex. The price for one EpiDex disc with a
diameter of 1 cm amounts to US$480 and, depending on
the wound surface area, between 6 and 12 discs are required
per treatment [24].
Nevertheless, Epidex disappeared from the market after
the ﬁnal supplier, Euroderm, went bankrupt in 2014. The
original manufacturer, Modex Therapeutics, fused with
IsoTis, a company from the Netherlands in 2002. The wound
care portfolio was sold to DFB Pharmaceuticals (USA) one
year later. However, there are no wound care products on
the oﬃcial DFB pharmaceuticals webpage as of 2017.
5.3. Challenges and Complications in Clinical Use. Frequent
complications in burn patients after epidermal autograft
treatment comprise high failure rates, abundant scarring,
and fragile skin coverage [64]. Clinically, fragile skin cover-
age manifests in blistering and may be caused by a delay in
dermoepidermal junction formation [59]. However, the rate
of major complications is similar between patients treated
with CEAs or conventional grafting techniques [59].
A major and thus far unsolved problem is the variable
engraftment rate. Engraftment can be complicated by
wound infection [25, 42, 65] and depends on size and depth
of the wound. Age may also aﬀect the engraftment rate, with
some studies reporting younger patients showing higher
engraftment rates [65, 66]. Treated wounds require careful
primary and secondary wound coverage to prevent graft dis-
placement or damage. Moreover, CEAs can show signs of
hyperkeratosis [65].
5.3.1. Infections. Concurrent infections were speculated to
be a main reason for graft failure since the ﬁrst applica-
tion of CEAs [25]. Indeed, wound infection was the most
common adverse reaction in a trial assessing the commer-
cially available product EpiDex for ulcers treatment [24].
These infections were so far treated with systemic antibiotics
or topical antimicrobials and antiseptics (for details see
Drug Interactions).
A successfully treated infection does not impair subse-
quent epithelialization [67], but some bacterial species cause
complications or even graft failure requiring regrafting. For
instance, Pseudomonas aeruginosa destroys split-thickness
skin grafts as well as epidermal autografts [30, 68]. Similarly,
Staphylococcus haemolyticus induces graft destruction and
concurrent bleeding at the treatment location, which in some
cases may even lead to death [28].
Moreover, graft failure can also be caused by the “melt-
ing graft-wound syndrome.” This syndrome is character-
ized by increasing loss of epithelium from a healed burn
wound, a formerly well-taken graft or donor site, lack of
signs of systemic infection, and absence of inﬂammation
or cellulitis of the surrounding skin [69]. Streptococcus spe-
cies may be responsible for epithelial cell loss, but cases
without bacterial manifestation have also been reported
[63]. Further investigation of this phenomenon is therefore
needed [70].
A carefully prepared wound bed and eﬀective infection
control are important prerequisites for proper engraftment
[58], reﬂected in the application notes of commercially avail-
able products. For instance, Apligraf must not be used on
infected ulcers [71]. One of the causes making CEAs vulner-
able for infections is inferior perfusion of the graft. Hence,
strategies enhancing vascularization and augmenting supply
as well as immunologic defense capabilities in the wound
area upon transplantation need to be developed [49].
5.3.2. Drug Interactions. The potential interaction between
drugs commonly applied to patients with skin deﬁcits and
grafted material is clinically relevant. As reviewed above,
infections are a common problem in CEA application and
can damage or destroy the graft.
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Keratinocytes in the upper graft layers are the most
important cell population for graft functionality. These cells
shield underlying tissue from environmental inﬂuences.
Hence, several topical antimicrobial substances used to ﬁght
common infections in patients have been tested on cultured
keratinocytes to assess potential toxicity on transplanted
grafts. Aminoglycosides, macrolides/lincosamides, glycopep-
tides, and polypeptides exert cytotoxic eﬀects on keratino-
cytes, with cytotoxicity increasing in the listed order. In
addition, nonsynthetic antibiotic substances are less cyto-
toxic than synthetic or antifungal substances [72].
Table 2 summarizes the main results of toxicity studies
using keratinocytes. The least toxic antibiotics with respect
to clinically applied dosages can be ranked as follows
(increasing order of toxicity): neomycin, clindamycin, framy-
cetin, erythromycin, and gentamycin. These substances are
therefore recommended for use with epidermal grafts includ-
ing CEAs. Toxicity of topically applicable antiseptics is (in
that order, highest toxicity ﬁrst) silver sulfadiazine, silver
nitrate solution, cerium-silver-sulfadiazine, and silver nitrate
plus chlorhexidine.
An interesting point of ongoing discussion is the systemic
intake of topical agents and related side eﬀects. This may be
relevant when antibiotics are applied to large body surface
areas, for instance, after severe burn injury. Only a few inves-
tigations have addressed this problem so far. For example,
the gentamycin concentration in the blood after topical
application on full-thickness wounds was clearly below the
recommended maximum level in a pig study, reducing safety
concerns of topical application on moderately sized skin
wounds [73].
5.3.3. Ulceration and Malignant Degeneration. Treatment
with CEAs can also lead to more severe complications in sin-
gle cases. For instance, several secondary lesions and ulcera-
tions of unknown origin were observed in a burn patient
following extensive epi-SC-derived autograft transplantation.
Even an invasive squamous cell carcinoma representing a
potential malignant transformation was observed 13.5 years
after the initial treatment, followed by another seven carcino-
mas over a time period of 10 years [74, 75]. The use of cholera
toxin or isoproterenol during the in vitro cultivation of epi-
SCs may be one reason for this transformation. It can, how-
ever, not be concluded that carcinoma induction is an
adverse event that can solely be traced back to the cultivation
and transplantation of CEAs, since malignant transforma-
tions can also emerge from burn scars over time [74–76].
These observations illustrate the necessity for continuous
and thorough follow-up of transplant patients [77].
5.3.4. Cosmetic Aspects. All currently available grafts fail to
regenerate skin appendices such as sweat or sebaceous
glands and hair. Particularly, lack of the latter can lead to
suboptimal cosmetic results even if wound healing was suﬃ-
cient. A single case was reported of a large (10× 8 cm) cranial
full-thickness burn wound treated with a tissue-engineered
dermal template [67]. Hair follicles were micrografted into
the template and, being a stem cell source, contributed to
complete reepithelialization within just 37 days. However,
only very minor regrowth of hair was observed one year
after treatment.
Very recent preclinical studies reported the possibility to
generate fully functional hair follicles by stem cell manipula-
tion [78]. Similar results were reported for protocols using
induced pluripotent stem cells [79]. Such techniques may
in the future be used to promote hair regrowth on trans-
planted skin, but require further reﬁnement for application
in patients.
6. Summary
Autologous and allogeneic skin grafts cultured from skin-
derived stem cells can eﬃciently support wound healing
and are a valuable addition to conventional skin grafting
approaches. The combination with biomaterials can augment
stability and functionality of the transplants. A number of
Table 2: Experiences with drug interactions on skin cells.
Chemical name Brand name Toxicity References
Fusidic acid, tetracycline,
virginiamycin
Diverse High toxicities at clinically applied doses [72]
Gentamycin Diverse
Favorable safety proﬁle at low concentrations
[73, 83]Impaired cell migration and proliferation at higher concentrations
(0.1 to 1.0mg/mL), thus the clinically applied dose in topical
preparations (about 0.1% or 1mg/g) may impair cell function
Mafenide Sulfamylon®
Cytotoxic even at lower local concentrations, therefore not
suitable as a topical agent
[83]
Phenoxyethanol Diverse Promising alternative to antiseptic solutions [72]
Polymyxin B Diverse Dose-dependent detrimental eﬀects [83]
Polymyxin B sulfate in
combination with bacitracin
Polysporin®
Impaired proliferation at higher concentrations with the
main eﬀect being mediated by polymyxin B sulfate
[83]
Polymyxin B sulfate in combination
with neomycin sulfate
Neosporin®
Much more favorable safety proﬁle, containing far less
polymyxin B but exerting excellent antimicrobiotic eﬀects,
discussed as a well-suited topical antibiotic
[83]
Povidone-iodine Diverse Toxicity depends on the presence of serum (higher without) [72]
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successful clinical trials have been completed, and bioengi-
neered skin grafts are available as therapeutic products.
Nevertheless, the use of these products is still limited. First,
they are still expensive to manufacture, limiting widespread
applicability. Automation of graft production and applica-
tion may help to overcome this limitation. Second, treatment
results are often limited since skin appendices (glands, hair)
are usually not regenerated. Advanced stem cell and tissue
engineering approaches may provide solutions for this in
the future. Third, results of in vivo (rodent) studies are only
partially comparable to the patient situation, warranting the
development of novel models including large animal experi-
ments to achieve better comparability. Moreover, potential
interactions between topical and systemic drugs and the
stem cell-derived graft should be investigated in more
detail. Altogether, this will augment the therapeutic value
and clinical applicability of skin grafts.
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